Falgun Shah
Overview
Explore the profile of Falgun Shah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
240
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sheridan R, Karnachi P, Tudor M, Xu Y, Liaw A, Shah F, et al.
J Chem Inf Model
. 2020 Mar;
60(4):1969-1982.
PMID: 32207612
Given a particular descriptor/method combination, some quantitative structure-activity relationship (QSAR) datasets are very predictive by random-split cross-validation while others are not. Recent literature in modelability suggests that the limiting issue...
2.
Shah F, Bell I
J Med Chem
. 2020 Feb;
63(14):7447-7457.
PMID: 32091882
The term "sulfa allergy", originally coined for the sulfonamide antibiotics, has become associated with any drugs that contain a sulfonamide moiety. This raises a question: should medicinal chemists avoid making...
3.
Aleo M, Shah F, Allen S, Barton H, Costales C, Lazzaro S, et al.
Chem Res Toxicol
. 2019 Sep;
33(1):223-238.
PMID: 31532188
The hepatic risk matrix (HRM) was developed and used to differentiate lead clinical and back-up drug candidates against competitor/marketed drugs within the same pharmaceutical class for their potential to cause...
4.
Schnute M, Wennerstal M, Alley J, Bengtsson M, Blinn J, Bolten C, et al.
J Med Chem
. 2018 Aug;
61(23):10415-10439.
PMID: 30130103
The nuclear hormone receptor retinoic acid receptor-related orphan C2 (RORC2, also known as RORγt) is a promising target for the treatment of autoimmune diseases. A small molecule, inverse agonist of...
5.
Shah F, Medvedev A, Wassermann A, Brodney M, Zhang L, Makarov S, et al.
Toxicol Sci
. 2017 Nov;
162(1):177-188.
PMID: 29106686
Drug-induced liver injury (DILI) is a leading cause of drug attrition during drug development and a common reason for drug withdrawal from the market. The poor predictability of conventional animal-based...
6.
Shah F, Stepan A, OMahony A, Velichko S, Folias A, Houle C, et al.
Cell Chem Biol
. 2017 Jul;
24(7):858-869.e5.
PMID: 28669525
Cutaneous reactions represent one of the most common adverse drug effects observed in clinical trials leading to substantial compound attrition. Three negative allosteric modulators (NAMs) of metabotropic glutamate receptors (mGluRs),...
7.
Aleo M, Shah F, He K, Bonin P, Rodrigues A
Chem Res Toxicol
. 2017 May;
30(6):1365.
PMID: 28520417
No abstract available.
8.
Aleo M, Shah F, He K, Bonin P, Rodrigues A
Chem Res Toxicol
. 2017 Apr;
30(5):1219-1229.
PMID: 28437613
The role of bile salt export protein (BSEP) inhibition in drug-induced liver injury (DILI) has been investigated widely, while inhibition of the canalicular multidrug resistant protein 3 (MDR3) has received...
9.
Lee E, Steeno G, Wassermann A, Zhang L, Shah F, Price D
Bioorg Med Chem Lett
. 2016 Dec;
27(3):653-657.
PMID: 28011216
Drug discovery programs often face challenges to obtain sufficient duration of action of the drug (i.e. seek longer half-lives). If the pharmacodynamic response is driven by free plasma concentration of...
10.
Shah F, Leung L, Barton H, Will Y, Rodrigues A, Greene N, et al.
Toxicol Sci
. 2015 Jul;
147(2):500-14.
PMID: 26206150
Severe drug-induced liver injury (DILI) remains a major safety issue due to its frequency of occurrence, idiosyncratic nature, poor prognosis, and diverse underlying mechanisms. Numerous experimental approaches have been published...